DexCom, Inc. (DXCM)
NASDAQ: DXCM · Real-Time Price · USD
68.18
-1.05 (-1.52%)
At close: Oct 29, 2025, 4:00 PM EDT
68.19
+0.01 (0.01%)
After-hours: Oct 29, 2025, 4:28 PM EDT
DexCom Revenue
DexCom had revenue of $1.16B in the quarter ending June 30, 2025, with 15.21% growth. This brings the company's revenue in the last twelve months to $4.30B, up 9.30% year-over-year. In the year 2024, DexCom had annual revenue of $4.03B with 11.34% growth.
Revenue (ttm)
$4.30B
Revenue Growth
+9.30%
P/S Ratio
6.31
Revenue / Employee
$417,553
Employees
10,300
Market Cap
26.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.03B | 410.70M | 11.34% |
| Dec 31, 2023 | 3.62B | 712.50M | 24.49% |
| Dec 31, 2022 | 2.91B | 461.30M | 18.84% |
| Dec 31, 2021 | 2.45B | 521.80M | 27.08% |
| Dec 31, 2020 | 1.93B | 450.70M | 30.54% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
DXCM News
- 1 day ago - DexCom Faces New Reports Of Deaths Linked To G7 Glucose Monitor - Benzinga
- 2 days ago - Dexcom Appoints Euan Ashley to Board of Directors - Business Wire
- 2 days ago - Halper Sadeh LLC Encourages DexCom, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 6 days ago - 10 stocks primed for growth in the S&P 500's cheapest sectors - Market Watch
- 23 days ago - DexCom May Be The Most Underrated Growth Story In Healthcare - Seeking Alpha
- 27 days ago - Dexcom Schedules Third Quarter 2025 Earnings Release and Conference Call for October 30, 2025 at 4:30 p.m. Eastern Time. - Business Wire
- 5 weeks ago - Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA - Benzinga
- 6 weeks ago - Dexcom Spotlights Upcoming Feature Launches, Improved Health Outcomes and Cost-Effectiveness With Dexcom Glucose Biosensing at EASD 2025 - Business Wire